Report topline results for RSVHR Phase 2 study of zelicapavir
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 10 Feb 2025
- Due
- 30 Sep 2025
- Delivered
- 29 Sep 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Enrollment in RSVHR is progressing, and the company is targeting completion in the current Northern Hemisphere RSV season with topline data in the third quarter of 2025.”
What we found
Evidence strength B What the grades mean
Enanta announced positive topline results from the RSVHR Phase 2b zelicapavir study on September 29, 2025, within the targeted Q3 2025 window.
-
B Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults Press release announcing positive RSVHR topline results dated Sept 29, 2025
-
B Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 Company reaffirms it is on track to report RSVHR topline data in September 2025
-
B Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir BusinessWire release confirming RSVHR topline data release date
Checked 16 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Language
- Aspirational (“aims”, “intends”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second checkThe evidence document could not be read for a second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Enanta Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ENTA-000418 · Corrections policy